287389-38-2Relevant academic research and scientific papers
Dephosphorylation and biodistribution of 1-13C-phospholactate in vivo
Shchepin, Roman V.,Pham, Wellington,Chekmenev, Eduard Y.
, p. 517 - 524 (2014/08/05)
Here, we present a new approach for the delivery of a metabolic contrast agent for in vivo molecular imaging. The use of a phosphate-protecting group that facilitates parahydrogen-induced polarization of 1-13C- phospholactate potentially enables the in vivo administration of a hydrogenated hyperpolarized adduct. When injected, nonhyperpolarized 1-13C- phospholactate is retained in the vasculature during its metabolic conversion to 1-13C-lactate by blood phosphatases as demonstrated here using a mucin 1 mouse model of breast cancer and ex vivo high-resolution 13C NMR. This multisecond process is a suitable mechanism for the delivery of relatively short-lived 13C and potentially 15N hyperpolarized contrast agents using -OH phosphorylated small molecules, which is demonstrated here for the first time as an example of 1-13C- phospholactate. Through this approach, dl-1-13C-lactate is taken up by tissues and organs including the liver, kidneys, brain, heart, and tumors according to a timescale amenable to hyperpolarized magnetic resonance imaging. The use of a phosphate-protecting group that facilitates parahydrogen-induced polarization of 1-13C-phospholactate potentially enables the in vivo administration of a hydrogenated hyperpolarized adduct. When injected, nonhyperpolarized 1-13C-phospholactate is retained in the vasculature during its metabolic conversion to dl-1-13C-lactate by blood phosphatases, which in turn taken up by tissues and organs according to a timescale amenable to hyperpolarized magnetic resonance imaging (MRI). This represents a new approach for in delivery of a metabolic hyperpolarized MRI contrast agent for molecular imaging. Copyright
